Peramivir was FDA approved last influenza season for emergency use with severe H1N1 infections. In this randomized trial, patients with influenza who received peramivir had significantly shorter symptom duration than those on placebo, with adverse event rates similar to placebo. Peramivir appears to be effective in reducing duration of symptoms, and well tolerated (abstract).
Share This Post
Categories
Related Posts
During the first two to three weeks of the pandemic in 2020, I was involved in a lot of meetings about the current status and future plans for the impending surge of COVID-19 patients we were anticipating. It was during that time we witnessed COVID-19 ravaging cities like New York City. In one of the […]
The COVID-19 pandemic has changed health care as we know it. It has sowed fear and doubt among the public and created endless questions without answers. Our hospitalized patients may wonder why they can’t have their families beside them and worry about contracting the virus in the hospital. Strict visitation policies only add to their […]
This article is part of a series in The Hospital Leader written by members of the Division of Hospital Medicine at Dell Medical School at The University of Texas in Austin, exploring lessons learned from the coronavirus pandemic and outlining an approach for creating COVID-19 Centers of Excellence. During the early months of the COVID-19 […]
Leave A Comment